A couple giving piggy back rides to two children outdoors

OUR THERAPIES DELIVER RELIEF

Imagine fewer trips to the bathroom. Fewer accidents. And resuming the relationships and activities you love.

FIND A SPECIALIST

COMMUNICATION IS CRITICAL

Evidence suggests that breakdowns in the bladder-brain communication pathway are the root cause of OAB and non-obstructive urinary retention.1-3 While other therapies focus on the bladder muscles, Medtronic therapies target the nerves, which is thought to help restore normal bladder function.*

Image showing a brain and a urinary system communicating

EXPLORE OUR BLADDER CONTROL THERAPIES:

Medtronic Bladder Control Therapy Delivered by the InterStim System
Medtronic Bladder Control Therapy Delivered by the NURO System

Expand All

PROVEN RESULTS

  • 84% satisfaction among those who use it6
  • 76% of people achieved success at 6 months compared to 49% who used
  • medications5,†
  • The only OAB therapy that provides better relief than medications5,7,8

The most common adverse events experienced during clinical studies included pain at implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations. Any of these may require additional surgery or cause return of symptoms.

Abdominal cross section showing the urinary and digestive systems

IS THIS THERAPY RIGHT FOR YOU?

SEE IF IT WORKS FOR YOU

Expand All

PROVEN TO RESTORE BLADDER FUNCTION‡

  • Restores bladder function by gently stimulating the tibial nerve
  • Thought to normalize control of the bladder’s natural reflexes
  • Delivered during 30-minute in-office sessions for 12 weeks
  • Followed by monthly maintenance sessions for potential long-term relief

Improves quality of life9 which may include going to the bathroom less often and getting back to activities you enjoy.

  • Reduces urgency, frequency, and accidents
  • Thought to normalize control of the bladder’s natural reflexes
  • Lasting relief without the side effects of medication or the need for self-catheterization10

Most common side effects of PTNM are temporary and include mild pain or skin inflammation at or near the stimulation site.

EXPECT A SIMPLE, EASY EXPERIENCE

*

Success with SNM is defined as a 50% or greater reduction in your troublesome bladder symptoms.

These patient groups were analyzed based on the treatment they were assigned: incomplete data was counted as ”failures.” Another analysis reported 61% of people achieved success with InterStim, compared to 42% who used medications.

Restored bladder function is defined as a measurable reduction in urinary frequency and/or urinary incontinence episodes following PTNM treatment.

1

Dasgupta R. Critchley HD, Dolan RJ, Fowler CJ. Changes in brain activity following sacral Neuromodulation for urinary retention. J Urol. 2005;174:2268-2272

2

Griffiths D, Derbyshire S, Stenger A, Resnick N. Brain control of normal and overactive bladder. J Urol. 2005;174:1862-1867.

3

Griffiths D, Tadic SD. Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. Neurourol Urodyn. 2008;27(6):466-474.

4

Noblett K, Siegel S, Mangel J, et al. Results of a Prospective, Multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn. 2014. doi:10.1002/nau.22707.

5

Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim® Therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34:224–230. DOI: 10.1002/nau.22544.

6

Foster RT Sr, Anoia EJ, Webster GD, Amundsen CL. In patients undergoing neuromodulation for intractable urge incontinence a reduction in 24-hr pad weight after the initial test stimulation best predicts long-term patient satisfaction. Neurourol Urodyn. 2007;26:213-217.

7

Visco A, Brubaker L, Richter HE et al. Anticholinergic Therapy vs. OnabotulinumtoxinA for Urgency Urinary Incontinence. New Engl J Med. 2012;367(19):1803-1813.

8

Peters KM, MacDiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055-1061.

9

Peters KM, Carrico DJ, et al. “Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial.” J Urol. 2010;183(4): 1438-1443.

10

Peters, K.M., D.J. Carrico, et al. (2013). “Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study.” J Urol. 189(6) 2194-2201.8.